Sun, Oct 26, 2014, 12:10 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

BioLife Solutions, Inc. Message Board

  • hwmccusker hwmccusker Apr 1, 2013 9:38 AM Flag

    Q4/12 and FY12 Results – STRONG BUY

    BLFS is growing its business while keeping high growth as the regenerative medicine market opportunity develops.” BLFS hold the leading supplier position for pre-formulated, clinical grade bio-preservation media products. We estimate that our HypoThermosol^® cell/tissue storage medium and CryoStor^® cryopreservation freeze media products are used in more than 50 clinical trial-stage cell and tissue based therapies in the regenerative medicine field; any 1 of which could generate $1 M per year in revenue, if regulatory and marketing approvals are obtained by our customers. BLFS closed at $0.29 on no volume on Thursday, 3/29/13. As traders stayed silent post seeking profit and always seems to pop back. I am still … optimistic about BLFS, now that Q4 and FY12 results are out – my expectations are on target – yet again as BLFS focuses another “rebound” play! The 50 day moving average is up to $0.30 and the 200 day average is up $0.28. The float is only 19.02 M as compared to outstanding shares of 69.67 M. I continue to reiterate this as a “STRONG BUY”

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • As positive as I am about the BLFS future, the fact remains that BLFS is still unprofitable. Until BLFS starts to be profitable I don't see how there will be any significant upside movement. In sum, unprofitability is still a major problem for BLFS.

2.11-0.05(-2.31%)Oct 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.